PTC Therapeutics, Inc.
PTCT
$50.57
$1.653.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.19% | 459.73% | -30.58% | 0.11% | -12.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.19% | 459.73% | -30.58% | 0.11% | -12.68% |
| Cost of Revenue | -15.77% | -6.90% | -6.26% | -0.83% | -25.63% |
| Gross Profit | 39.63% | 1,230.31% | -53.94% | 7.24% | 156.58% |
| SG&A Expenses | 22.68% | 10.49% | 11.00% | -9.19% | -21.42% |
| Depreciation & Amortization | 41.75% | -92.63% | -95.71% | -94.82% | -93.96% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.88% | -19.20% | -24.64% | -20.59% | -34.20% |
| Operating Income | -4.50% | 2,228.29% | -608.69% | 55.46% | 72.35% |
| Income Before Tax | 17.12% | 1,197.84% | 39.70% | 41.18% | 63.90% |
| Income Tax Expenses | -146.13% | 819.56% | -2,188.56% | 125.77% | 134.84% |
| Earnings from Continuing Operations | 34.61% | 1,046.28% | 57.71% | 19.79% | 50.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.61% | 1,046.28% | 57.71% | 19.79% | 50.13% |
| EBIT | -4.50% | 2,228.29% | -608.69% | 55.46% | 72.35% |
| EBITDA | -3.55% | 9,824.03% | -110.86% | 16.72% | 62.18% |
| EPS Basic | 35.81% | 1,026.68% | 58.65% | 21.40% | 51.43% |
| Normalized Basic EPS | 7.71% | 1,164.64% | 283.87% | 38.65% | 50.02% |
| EPS Diluted | 35.79% | 936.67% | 58.65% | 21.40% | 51.43% |
| Normalized Diluted EPS | 7.71% | 1,062.71% | 283.87% | 38.65% | 50.02% |
| Average Basic Shares Outstanding | 1.86% | 2.12% | 2.27% | 2.05% | 2.67% |
| Average Diluted Shares Outstanding | 1.86% | 12.93% | 2.27% | 2.05% | 2.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |